Cyclodextrin-loaded nanobubbles reduce cholesterol and atherosclerosis in vivo
Polymeric nanobubbles were prepared by using polybutlycyanoacrylate. The incorporation of near-infrared dye (IR780) resulted in a multimodal contrast NB, which
Tag: HPBCD
Ceftobiprole/SBECD complexes
This paper presents the theoretical calculations of the inclusion complex formation between native ceftobiprole, a promising antibiotic from the cephalosporin
Merger of Cyclo Therapeutics and Applied Molecular Transport
Cyclo Therapeutics, (Cyclo) a clinical stage company focused on developing therapies for rare and neurological diseases with limited treatment options,
Nanalysis Benchtop NMR with USP Monographs and Betadex
Following our recent publication “Molar Substitution Determination in Hydroxypropyl Betadex According to USP-NF/Ph. Eur. (1804) Monograph Method Using 1H Benchtop
HPBCD was tested as a possible therapeutic agent in Amyotrophic Lateral Sclerosis (ALS) model
Amyotrophic lateral sclerosis (ALS), also known as motor neurone disease (MND), is a rare and terminal neurodegenerative disease that results
Direct cyclodextrin based powder extrusion 3D printing of budesonide loaded mini-tablets for the treatment of eosinophilic colitis in paediatric patients
The purpose of this study was to combine direct powder extrusion (DPE) 3D printing and fluid bed coating techniques to
Comparison of cholesterol complexation with β-cyclodextrin derivatives: A combined theoretical and experimental study
This study [1] aimed to compare differences in interactions between cholesterol and β-cyclodextrin and its derivatives for selecting a suitable
Molecular Mind Games: The Medicinal Action of Cyclodextrins in Neurodegenerative Diseases
This work presents the most recent advances in the research and clinical use of HPβCD against Niemann–Pick disease, a congenital
An unprecedented example for sole cyclodextrins as API: an ophthalmic composition with hydroxypropyl betadex, alone
A paradigm shift in cyclodextrin technology started with the design, development and marketing of Sugammadex®/Bridion®, and followed by designation of
Unraveling the interaction of drug (Diflunisal) with cyclodextrin and protein (Lysozyme) by fluorescence spectroscopy
Understanding the interaction between the drug:carrier complex and protein is essential for the development of a new drug-delivery system. However,